Reimbursement & Directory Validation Update

Reimbursement Change
Effective Oct. 1, BCBSWY will begin using J-code level pricing for J-1745 (infliximab). We will no longer be pricing this medication at the NDC code level. Reimbursement will be at the biosimilar rate.

Directory Validation Tip
In Availity, beneath the user account, please select “Manage My Organization” to make updates. (See screenshot below.) Additional instructions are located here to help you find NPI and tax ID combinations. This helps facilitate compliance with the No Surprises Act (NSA) provider directory validation requirements. The NSA requires you confirm this information with us every 90 days, so your information can continue to be listed in our public directory.

Share

Related Posts
Intraocular Lenses Billing Code Change, Therapy Modifiers, Availity and More
Coding Advice – Modifiers As of 9/1/2023, BCBSWY will no longer permit the usage of modifiers CO (Occupational Therapy Assistant) or CQ (Physical Therapy…
Anesthesia Reimbursement, Nerve Conduction & More
Anesthesia Reimbursement Updates Effective 4/1/2023, we have updated our pricing on 01967 to allow eight additional units above the base instead of the previous…
Hearing Aids, National Physicians Week & More
Hearing Aid Submission Effective 7/1/2023, BCBSWY will reimburse hearing aids at 100% of submitted invoices. Providers should bill the cost of professional services associated…

Fewer Hassles. Better Service.

Back to Top